Dyne Therapeutics Inc (DYN)
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company focused on neuromuscular diseases in the United States. The company is developing a pipeline of therapeutics for muscle-related conditions, including myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease, along with programs targeting rare skeletal muscle, cardiac, and metabolic muscle disorders. Its work is centered on the FORCE platform, which is designed to deliver disease-modifying therapeutics. Dyne Therapeutics was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Its common stock is listed on NASDAQ under the symbol DYN.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DYN
|
$20.79
|
-12.9% Downside
|
Fair
|
$39.33
|
64.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
-8.8x
|
4.6x
|
—
|
3.877 B
|
3.189 B
|
4.2%
|
99.7%
|
8.5
|
—
|
102.3%
|
